press releases

Half-year liquidity contract statement for LYSOGENE
Half-year liquidity contract statement for LYSOGENE 150 150 Lysogene

Paris, France — 05 July 2021 at 06:00 pm CEST — Lysogene (FR0013233475 – LYS), a…

LYSOGENE releases the results from June 25, 2021 ordinary annual and extraordinary general meeting
LYSOGENE releases the results from June 25, 2021 ordinary annual and extraordinary general meeting 150 150 Lysogene

Shareholders approved all proposed resolutions Paris, France — 25 June 2021 at 06:00 pm CEST —…

Lysogene Enters into an Exclusive Worldwide License Agreement with SATT Conectus for a Gene Therapy Candidate for the Treatment of the Fragile X Syndrome
Lysogene Enters into an Exclusive Worldwide License Agreement with SATT Conectus for a Gene Therapy Candidate for the Treatment of the Fragile X Syndrome 150 150 Lysogene

Paris, France — 11 June 2021 at 08:00 am CEST — Lysogene (FR0013233475 – LYS), a…

Lysogene Enters into an Exclusive Worldwide License Agreement with SATT Conectus for a Gene Therapy Candidate for the Treatment of the Fragile X Syndrome
Lysogene Enters into an Exclusive Worldwide License Agreement with SATT Conectus for a Gene Therapy Candidate for the Treatment of the Fragile X Syndrome 150 150 Lysogene

Strengthening of Lysogene’s pipeline with a new drug candidate for a pathology with high unmet…

Lysogene Announces First Patient Dosed with LYS-GM101 Investigational Gene Therapy for the Treatment of GM1 Gangliosidosis
Lysogene Announces First Patient Dosed with LYS-GM101 Investigational Gene Therapy for the Treatment of GM1 Gangliosidosis 150 150 Lysogene

Second Lysogene CNS gene therapy program to enter the clinicOngoing enrollment of a total of…

LYSOGENE – Meeting Notice of the Annual Ordinary and Extraordinary General Meeting to be held on 25 June 2021
LYSOGENE – Meeting Notice of the Annual Ordinary and Extraordinary General Meeting to be held on 25 June 2021 150 150 Lysogene

Paris, France — 20 May 2021 at 06:00 pm CEST — Lysogene (FR0013233475 – LYS), a…

Lysogene Reports its Cash Position as of 31 March 2021
Lysogene Reports its Cash Position as of 31 March 2021 150 150 Lysogene

Cash and cash equivalents of €20.0 million[1] as of 31 March 2021 Paris, France —…

Lysogene Announces Filing of 2020 Universal Registration Document
Lysogene Announces Filing of 2020 Universal Registration Document 150 150 Lysogene

Paris, France — 13 April 2021 at 06:00 pm — Lysogene (FR0013233475 – LYS), a…

Lysogene Reports Full Year 2020 Financial Results and Provides Operational Update
Lysogene Reports Full Year 2020 Financial Results and Provides Operational Update 150 150 Lysogene

Positive biomarker data reported with LYS-SAF302 for the treatment of MPS IIIANew program entering the…

Lysogene Reports its Cash Position as of 31 December 2020
Lysogene Reports its Cash Position as of 31 December 2020 150 150 Lysogene

Cash and cash equivalents of €18.8 million[1] as of 31 December 2020 Paris, France —…

Lysogene COVID-19 update

Find out More

Lysogene is developing therapies for children with CNS diseases.

Delivering Gene Therapy’s Promise

About Us
Our Science
Meet the Team
Diseases
Resources

Contact Us
Careers
Transparency
Compassionate Use Policy

©2022 Lysogene. All rights reserved.

Cookie Policy
Privacy Policy
Legal Notice

Get In Touch

Don’t hesitate to contact us if you need more help.

    Start Typing